Cir­cas­sia forges a $300M COPD sales/de­vel­op­ment pact for US rights on two As­traZeneca drugs

Barred at the FDA this morn­ing on one big new drug, As­traZeneca has dick­ered away US rights to two of its res­pi­ra­to­ry meds for COPD, in­clud­ing an ex­per­i­men­tal ef­fort aimed at a reg­u­la­to­ry fil­ing next year.

The UK’s Cir­cas­sia — dealt a se­vere set­back last sum­mer — is tak­ing the lead on pro­mot­ing Tu­dorza in the US, with an op­tion on full com­mer­cial rights as the deal ma­tures. And As­traZeneca will al­so hand over Du­ak­lir once it’s wrapped de­vel­op­ment work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER